Breaking News

Tweet TWEET

Oculus Innovative Sciences Introduces Two New Microcyn(R) Advanced Wound Care Products for U.S. Prescription Wound Care Market

Oculus Innovative Sciences Introduces Two New Microcyn(R) Advanced Wound Care
Products for U.S. Prescription Wound Care Market

  *New three-ounce Microcyn® Skin & Wound Spray HydroGel delivers wound
    hydrogel to entire wound site via innovative spray application
  *Microcyn Skin & Wound Care now available in convenient two-ounce bottle
    for both clinical and economical in-home patient use

PETALUMA, Calif., Jan. 7, 2014 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences,
Inc. (Nasdaq:OCLS), a global healthcare company that designs, manufactures and
markets prescription and non-prescription products in 31 countries, today
introduced two new products to its U.S. family of Microcyn®-based advanced
wound care products.

An innovative advance in hypochlorous acid hydrogel technology, Microcyn®
Wound & Skin Spray HydroGel is now available in a spray formulation, allowing
it to be easily and conveniently sprayed directly onto the wound site.
Available in a three-ounce spray bottle, this newest advance in hydrogel
technology is reimbursable via HCPCS #A6248.

The second product is the proven and easy-to-use Microcyn® Wound & Skin Care
with preservatives, which is now available for the first time in a multi-use
two-ounce spray bottle. Used to cleanse, irrigate and aid in the debridement
of a vast array of chronic and acute wounds, Microcyn® can be used prior to a
variety of wound healing products and methods including products with silver,
enzymatic debriders, growth factors, tissue-engineered products and dermal
substitutes.The reduced bottle size allows it to be used both in the clinic,
as well as economically dispensed or prescribed for patients' in-home use.

"I've integrated the original Microcyn advanced wound care products quite
successfully into my practice for years," said Dr. Tom Wolvos, Arizona surgeon
and author of the Scottsdale Wound Management Guide. "This latest advance,
with a unique hydrogel formulation that can actually be sprayed on the wound,
is truly innovative and welcomed.It allows the hydrogel to be easily and
comprehensively applied to a wound site.And the economy-sized Microcyn
solution is ideal for patients to use at home with far less impact on their
healthcare budget."

Microcyn Technology is a powerful solution that provides an optimal wound
healing environment.It does not contain antibiotics, and as a result,
evidence to date indicates it does not promote antibiotic-resistance in
bacteria.Helping reduce wound odor via the removal of necrotic tissue,
Microcyn also assists in the physical removal of biofilm, a major deterrent in
wound healing.Other offerings in the Microcyn family of products include an
irrigation solution and a negative-pressure wound therapy solution available
in pharmasling® bottles.

These two newest Microcyn-based products are in stock and now available to
healthcare professionals. For more information, pricing or ordering visit
www.oculusis.com or phone 1-800-759-9305.

About Oculus Innovative Sciences

Oculus Innovative Science is a global healthcare company that designs,
manufactures and marketsprescription and non-prescription products in 31
countries. The company's products are used to treat patients in
surgical/advanced wound management, dermatology, women's health and animal
health; addressing the unmet medical needs of these markets—while raising the
standard ofpatient care and lowering overall healthcare costs. The company's
headquarters are in Petaluma, California, with manufacturing operations in the
United States and Latin America. More information can be found
atwww.oculusis.com.

Forward-Looking Statements

Except for historical information herein,matters set forth in this press
release are forward-looking within the meaning of the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995, including statements
about the Company's commercial and technology progress and futurefinancial
performance. These forward-looking statements are identified by the use of
words such as "growth," "expansion" and"build,"among others. Forward-looking
statements in this press release are subject to certain risks and
uncertainties inherent in the Company's business that could cause actual
results to vary, includingsuchrisks thatregulatory clinical and guideline
developments may change,scientific data may not be sufficient to meet
regulatory standards or receipt of required regulatory clearances or
approvals,clinical results may not be replicated in actual patient
settings,protection offered bythe Company'spatents and patent applications
may be challenged, invalidated or circumvented by its competitors,the
available market fortheCompany'sproducts will not be as large as
expected,the Company'sproducts will not be able to penetrate one or more
targeted markets,revenues will not be sufficient to fund further development
and clinical studies, the Company may not meet itsfuture capital needs, and
its ability to obtain additional funding, as well as uncertainties relative to
varying product formulations and a multitude of diverse regulatory and
marketing requirements in different countries and municipalities, and other
risks detailed from time to time in the Company's filings with the Securities
and Exchange Commission including the annual report on Form 10-K for theyear
ended March 31, 2013. Oculus Innovative Sciences disclaims any obligation to
update these forward-looking statements except as required by law.

Oculus and Microcyn Technology are trademarks or registered trademarks of
Oculus Innovative Sciences, Inc. All other trademarks and service marks are
the property of their respective owners.

Media and Investor Contact:

High-resolution product photos available.

CONTACT: Oculus Innovative Sciences, Inc.
         Dan McFadden
         VP of Public and Investor Relations
         (425) 753-2105
 
Press spacebar to pause and continue. Press esc to stop.